<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282241</url>
  </required_header>
  <id_info>
    <org_study_id>H13-02843</org_study_id>
    <nct_id>NCT02282241</nct_id>
  </id_info>
  <brief_title>Melatonin for Delirium Prophylaxis</brief_title>
  <official_title>A Randomized Double-Blind Placebo-Controlled Study on the Use of Melatonin for the Prevention of Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delirium is a common complication of illness especially among the elderly with serious&#xD;
      sequelae including increased mortality, morbidity and length of stay. This neuropsychiatric&#xD;
      emergency has key features including acute onset, fluctuating level of consciousness, poor&#xD;
      attention and cognitive deficits with a presentation which may include hallucinations and&#xD;
      delusions.&#xD;
&#xD;
      A critical precipitating and maintaining feature of delirium is disrupted sleep. Melatonin is&#xD;
      a widely available natural health product with evidence in normalizing circadian rhythms and&#xD;
      sleep. There is also preliminary evidence that melatonin can be used to prevent the&#xD;
      development of delirium in hospitalized patients. We hypothesize that daily administration of&#xD;
      melatonin (1.5mg) in the evening, beginning at first admission to hospital and continuing for&#xD;
      14 days, will lead to decreased rates of delirium compared to placebo-treated comparison&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Project never began&#xD;
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium (Confusion Assessment Method)</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Screening will be performed by a research assistant using the Confusion Assessment Method, and those with positive screening diagnosed by a study physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confusion (Confusion Assessment Method scores)</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Confusion Assessment Method scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of restraints</measure>
    <time_frame>Within 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Code White (Violence)</measure>
    <time_frame>Within 14 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Within 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to delirium</measure>
    <time_frame>Within 14 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Discharge Functional Status (Physiotherapist or Occupational therapist assessed)</measure>
    <time_frame>Within 6 months</time_frame>
    <description>Physiotherapist or Occupational therapist assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Discharge Disposition (Unchanged from pre-admission Home Home with supports Rehabilitation Assisted living)</measure>
    <time_frame>Within 6 months</time_frame>
    <description>Unchanged from pre-admission Home Home with supports Rehabilitation Assisted living</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep (Hours slept according to nursing records)</measure>
    <time_frame>Within 14 days</time_frame>
    <description>Hours slept according to nursing records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients given once daily placebo (cellulose) orally in the evening, for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  65 years of age or greater&#xD;
&#xD;
          -  Admitted to hospital under the care of the hospitalist service or sub-acute medicine&#xD;
             wards.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those who are suspected to be delirious at the time of their initial presentation;&#xD;
&#xD;
          -  those who are already taking melatonin prior to admission;&#xD;
&#xD;
          -  those who are not expected to live more than 48 hours;&#xD;
&#xD;
          -  those suffering severe dementia (as indicated by a score of 6-7 on the Global&#xD;
             Deterioration Scale adapted by Dr. Doug Drummond from Reisberg et al. (Reisberg 1982);&#xD;
&#xD;
          -  those who are unable to reliably take oral medications;&#xD;
&#xD;
          -  those presenting with an intracranial bleed, seizure or acute stroke;&#xD;
&#xD;
          -  those with a known allergy or adverse reaction to the study compounds;&#xD;
&#xD;
          -  those who cannot be evaluated initially because of depressed level of consciousness or&#xD;
             inability to communicate;&#xD;
&#xD;
          -  those anticipated to require surgery early in their hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter KY Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver Coastal Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Peter Y Chan</investigator_full_name>
    <investigator_title>Dr. Peter Chan</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Sleep</keyword>
  <keyword>Delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

